We propose a prospective, randomized, double blinded outcome study in which patients undergoing operative procedures requiring cardiopulmonary bypass (CPB) with aortic cross clamping will be randomly assigned to receive amiodarone, lidocaine, or saline placebo prior to removal of the aortic cross clamp. Specifically, we will test the hypothesis that amiodarone is superior to both lidocaine and...
Date First Received: December 21, 2007
Last Updated: February 9, 2010
Verified by: Mayo Clinic, February 2010
Clinical Trial Phase: N/A | Start Date: November 2007
Overall Status: Recruiting
Estimated Enrollment: 360
Brief Summary
Official Title: “The Use of Amiodarone vs. Lidocaine and Placebo for the Prevention of Ventricular Fibrillation After Myocardial Reperfusion During Cardiopulmonary Bypass”
Condition Keyword(s):
Intervention(s):
We propose a prospective, randomized, double blinded outcome study in which patients undergoing operative procedures requiring cardiopulmonary bypass (CPB) with aortic cross clamping will be randomly assigned to receive amiodarone, lidocaine, or saline placebo prior to removal of the aortic cross clamp. Specifically, we will test the hypothesis that amiodarone is superior to both lidocaine and saline in the prevention of reperfusion ventricular fibrillation after aortic cross clamp removal
Study Type: Interventional
Study Design: Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Study Primary Completion Date: December 2010
Intervention(s) in this Clinical Trial
- Drug: lidocaine
- 1.5 mg/kg
- Drug: amiodarone
- 300 mg
- Drug: placebo
- saline
Arms, Groups and Cohorts in this Clinical Trial
- Placebo Comparator: 1
- saline
- Active Comparator: 2
- Active Comparator: 3
Outcome Measures for this Clinical Trial
Primary Measures
- Our primary outcome will be the incidence of ventricular fibrillation requiring defibrillation during the 60 minute period following myocardial reperfusion
- Time Frame: 60 min
Safety Issue?: No
- Time Frame: 60 min
Secondary Measures
- incidence of arrhythmias other than ventricular fibrillation, number of defibrillation attempts required, highest dose of energy and current required for defibrillation,
- Time Frame: daily
Safety Issue?: No
- Time Frame: daily
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Patients between 18 and 100 years of surgery undergoing cardiac surgery
Exclusion Criteria:
- Women wishing to become preganat within 6 months of surgery
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Mayo Clinic
Overall Clinical Trial Officials and Contacts
William J Mauermann, MD Principal Investigator clinical instructor
Overall Contact: William J Mauermann, MD 507/255-4240 mauermann.william@mayo.edu
Additional Information
Information obtained from ClinicalTrials.gov on March 18, 2010
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00587483
Study ID Number: 06-005522
ClinicalTrials.gov Identifier: NCT00587483
Health Authority: United States: Institutional Review Board
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.